Evidence map›Paper›PMID 32922830›Full record

ArticleMultiple sclerosis journal - experimental, translational and clinical

Prevalence of mental disorders is higher in patients with multiple sclerosis than in the general population or in patients with rheumatoid arthritis in France.

Alice Guilleux, Jonathan Roux, David Travers, Emmanuelle Leray

Open access · goldAbstract read
In one paragraph

Article in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alice GuilleuxEHESP, REPERES, University of Rennes, France.ORCID https://orcid.org/0000-0002-7952-6261
Jonathan RouxEHESP, REPERES, University of Rennes, France.ORCID https://orcid.org/0000-0002-0158-2837
David TraversDepartment of Psychiatry, University Hospital CHU Pontchaillou, France.
Emmanuelle LerayEHESP, REPERES, University of Rennes, France.
École des Hautes Études en Santé Publique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMental disorders (MDs) in multiple sclerosis (MS) patients decreases treatment adherence and quality of life, and increases the risk of disability progression and care consumption.

objectiveThis study was to assess the prevalence of MDs in MS patients compared with healthy controls (HC) of the French general population and rheumatoid arthritis (RA) patients.

methodsThe 2015 prevalence of MDs for MS patients, RA patients and general population was estimated using a random population-based data sample from 'National Inter-Scheme Information System on Health Insurance' in the 2011-2015 period. Two control groups (1:5 ratio for the HC and 1:1 for the RA group) were matched to the MS group for year of birth, gender, area of residence and health insurance scheme.

resultsA total of 1145 MS patients were identified (sex ratio of 2.5 (F/M); median age 50 years). The prevalence of MDs was higher in the population of patients with MS (37.3%) than in the French general population (13.6%), and to a lesser extent in the RA group (21.1%) leading to the prevalence ratios of 2.8 (95% confidence intervals (CIs) 2.5-3.0) and 1.9 (95% CI 1.7-2.3), respectively.

conclusionsThis study confirmed that MS patients are at a higher risk of MDs than the French general population or RA patients.

Indexed as

health administrative databasesmental disordersMultiple sclerosis

Identifiers

PMID32922830
PMCPMC7457671
OpenAlexW3082904401

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.